FMP
Vanda Pharmaceuticals Inc.
VNDA
NASDAQ
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
4.13 USD
0.05 (1.21%)
2024
2023
2022
2021
198.77M
192.64M
254.38M
268.68M
0
14.8M
24.28M
25.63M
198.77M
177.84M
230.1M
243.05M
239.43M
191.8M
223.77M
200.89M
74.43M
76.82M
85.77M
75.36M
146.41M
112.88M
136.49M
124.05M
0
500k
2.6M
6.7M
0
112.38M
133.88M
117.35M
18.59M
2.09M
1.52M
1.48M
-40.66M
-13.95M
6.33M
42.16M
17.74M
20.29M
4.97M
199k
-22.92M
6.34M
11.3M
42.36M
-4.02M
3.83M
5.03M
9.21M
-18.9M
2.51M
6.28M
33.15M
-0.33
0.04
0.11
0.6
-0.33
0.04
0.11
0.58
58.15M
57.38M
56.46M
55.55M
58.15M
57.56M
56.98M
56.92M
-40.66M
-10.94M
9.06M
45.01M
2024
2023
2022
2021
-155.39M
-157.9M
-164.18M
-197.33M
-18.9M
2.51M
6.28M
33.15M
0
0
0
0
0
0
0
0
-174.29M
-155.39M
-157.9M
-164.18M
-18.9M
2.51M
6.28M
33.15M
2024
2023
2022
2021
12.68M
9.14M
10.97M
12.38M
0
3.01M
2.73M
2.84M
-490k
-383k
-679k
-552k
13.17M
6.51M
8.92M
10.1M
2024
2023
2022
2021
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in USD.